Aeterna Zentaris, Inc.
Records under this name other than the patents Aeterna Zentaris, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Aeterna Zentaris, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,921,318 | Application of Initial Doses of LHRH Analogues and Maintenance Doses of LHRH Antagonists for the Treatment of Hormone-Dependent Cancers and Corresponding Pharmaceutical Kits Held by another company In force · High confidence | In force | High confidence | |
| US 10,288,629 | Method of Assessing Growth Hormone Deficiency in Humans by a Macimorelin Containing Composition Held by another company In force · High confidence | In force | High confidence | |
| US 8,546,435 | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors Held by another company Lapsed on the fee record Ended Oct 1, 2025 · High confidence | Lapsed on the fee record | Ended Oct 1, 2025 | High confidence |
| US 7,887,817 | Process for preventing protozoal diseases Term ended Term ended Dec 22, 2024 · USPTO record | Term ended | Term ended Dec 22, 2024 | USPTO record |
| US 8,551,977 | Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals Term ended Term ended Jan 31, 2024 · USPTO record | Term ended | Term ended Jan 31, 2024 | USPTO record |
| US 8,389,497 | Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals Term ended Ended no later than Jul 30, 2023 · USPTO record | Term ended | Ended no later than Jul 30, 2023 | USPTO record |
| US 8,507,710 | Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals Lapsed on the fee record Ended Aug 13, 2021 · USPTO record | Lapsed on the fee record | Ended Aug 13, 2021 | USPTO record |
| US 8,470,776 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof Lapsed on the fee record Ended Jun 25, 2021 · USPTO record | Lapsed on the fee record | Ended Jun 25, 2021 | USPTO record |
| US 8,461,178 | Naphthyridine derivatives and the use thereof as kinase inhibitors Lapsed on the fee record Ended Jun 11, 2021 · USPTO record | Lapsed on the fee record | Ended Jun 11, 2021 | USPTO record |
| US 8,383,605 | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals Lapsed on the fee record Ended Feb 26, 2021 · USPTO record | Lapsed on the fee record | Ended Feb 26, 2021 | USPTO record |